Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

 
• By Derrick Gingery
  
FDA Advisory Committee Feature image
The Dermatologic and Ophthalmic Drugs Advisory Committee voted 12-0 that teprotumumab's benefits outweighed risks.

More from US FDA Performance Tracker

More from Regulatory Trackers